← All trials
NCT03926156
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 22, 2019
- Primary completion
- May 22, 2021
- Completion date
- Jun 23, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Rajaie Cardiovascular Medical and Research CenterLead sponsor
- Rajaie Cardiovascular Medical and Research CenterStudy chair
- National Institute for Medical Research and Development (NIMAD)Collaborator
- Abidi PharmaceuticalsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.